Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis

Wu, Shengwen; Ma, Cong-Chao; Li, Wenhui

doi:10.1186/s13000-015-0380-3

Cited by 25 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…181 However, initial results indicate HER2 overexpression may be predictive of resistance to EGFR-targeting monoclonal antibodies. 178,182 For example, in a cohort of 97 patients with RAS/BRAF wild-type metastatic CRC, median PFS on first-line therapy without an EGFR inhibitor was similar regardless of HER2 status.…”

Section: The Role Of Kras Nras and Braf Statusmentioning

confidence: 99%

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

Venook²,

Cederquist³

et al. 2017

J Natl Compr Canc Netw

749

515

View full text Add to dashboard Cite

OverviewColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2016, an estimated 95,270 new cases of colon cancer and approximately 39,220 cases of rectal cancer will occur. During the same year, an estimated 49,190 people will die of colon and rectal cancer combined. AbstractThis portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions. J Natl Compr Canc Netw 2017;15(3): 370-398 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: The Role Of Kras Nras and Braf Statusmentioning

confidence: 99%

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

Venook²,

Cederquist³

et al. 2017

J Natl Compr Canc Netw

749

515

View full text Add to dashboard Cite

show abstract

“…Several studies assessed HER2 status in CRC, with some authors reporting membranous erbB2 overexpression in 2%-11% and others reporting cytoplasmic overexpression in 47%-68% of cases[ 48 - 52 ]. However, it is currently acknowledged that the amplification of HER2 occurs in only 3% of CRC[ 53 ]. In accordance to this notion, a recent comprehensive genomic characterization of CRC revealed a recurrent amplicon at 17q21.1 in 4% of these tumors[ 54 ].…”

Section: Her2 Testing In the Digestive Systemmentioning

confidence: 99%

HER2aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists

Fusco¹,

Bòsari²

2016

WJG

View full text Add to dashboard Cite

Management of cancers of the digestive system has progressed rapidly into the molecular era. Despite the significant recent achievements in the diagnosis and treatment of these patients, the number of deaths for these tumors has currently plateaued. Many investigations have assessed the role of HER2 in tumors of the digestive system in both prognostic and therapeutic settings, with heterogeneous results. Novel testing and treatment guidelines are emerging, in particular in gastric and colorectal cancers. However, further advances are needed. In this review we provide a comprehensive overview of the current state-of-knowledge of HER2 alterations in the most common tumors of the digestive system and discuss the operational implications of HER2 testing.

show abstract

“…In addition, in the present study we were unable to examine whether the specimen type (i.e., biopsied vs. surgically resected) affects concordance. Fourth, Wu et al (25) reported the correlation between HER2 status and clinicopathological parameters through meta-analysis. Their meta-analysis included studies which used HER2 IHC as well as Western blot and fluorescence ISH, limiting the interpretation of the clinicopathological significance of HER2 IHC overexpression (25).…”

Section: Discussionmentioning

confidence: 99%

“…Fourth, Wu et al (25) reported the correlation between HER2 status and clinicopathological parameters through meta-analysis. Their meta-analysis included studies which used HER2 IHC as well as Western blot and fluorescence ISH, limiting the interpretation of the clinicopathological significance of HER2 IHC overexpression (25). The current study on the other hand included eligible studies that used HER2 IHC and carried out meta-analysis and diagnostic test accuracy review of HER2 IHC as well as concordance analysis between HER2 IHC and ISH, unlike the meta-analysis by Wu (25).…”

Section: Discussionmentioning

confidence: 99%